DnB Asset Management AS Has $20.92 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

DnB Asset Management AS grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 9.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 221,730 shares of the medical research company’s stock after acquiring an additional 19,379 shares during the quarter. DnB Asset Management AS’s holdings in Edwards Lifesciences were worth $20,916,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Alliancebernstein L.P. lifted its holdings in Edwards Lifesciences by 27.5% during the 4th quarter. Alliancebernstein L.P. now owns 21,874,280 shares of the medical research company’s stock valued at $1,632,040,000 after purchasing an additional 4,712,819 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Edwards Lifesciences by 3.8% in the 1st quarter. Wellington Management Group LLP now owns 15,850,055 shares of the medical research company’s stock valued at $1,311,275,000 after acquiring an additional 578,319 shares during the last quarter. Moneta Group Investment Advisors LLC grew its holdings in shares of Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock valued at $1,148,938,000 after buying an additional 15,384,593 shares during the period. Brown Advisory Inc. increased its stake in Edwards Lifesciences by 0.8% during the 4th quarter. Brown Advisory Inc. now owns 14,341,102 shares of the medical research company’s stock worth $1,069,990,000 after purchasing an additional 115,268 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 0.6% in the first quarter. Geode Capital Management LLC now owns 12,214,619 shares of the medical research company’s stock valued at $1,008,114,000 after buying an additional 78,376 shares during the period. Institutional investors own 79.25% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on EW. Royal Bank of Canada reaffirmed an “outperform” rating and set a $96.00 price target on shares of Edwards Lifesciences in a research report on Thursday, August 17th. Mizuho boosted their price target on Edwards Lifesciences from $95.00 to $102.00 in a research note on Monday, July 17th. Citigroup upped their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 in a research report on Monday, July 10th. TheStreet lowered shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a report on Wednesday, August 9th. Finally, 58.com reissued a “reiterates” rating on shares of Edwards Lifesciences in a research note on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $92.42.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,660 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $73.63, for a total value of $637,635.80. Following the completion of the sale, the insider now directly owns 213,794 shares in the company, valued at $15,741,652.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $73.71, for a total value of $331,695.00. Following the completion of the sale, the vice president now owns 39,503 shares of the company’s stock, valued at $2,911,766.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,660 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $73.63, for a total value of $637,635.80. Following the completion of the sale, the insider now directly owns 213,794 shares of the company’s stock, valued at approximately $15,741,652.22. The disclosure for this sale can be found here. Insiders sold 174,359 shares of company stock valued at $14,301,522 over the last 90 days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 1.2 %

Shares of EW stock opened at $74.02 on Friday. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $98.35. The company has a current ratio of 3.15, a quick ratio of 2.30 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average of $81.72 and a 200-day moving average of $83.95. The stock has a market cap of $45.00 billion, a price-to-earnings ratio of 32.75, a PEG ratio of 3.95 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.01. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.51 billion. During the same period in the prior year, the company posted $0.63 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.4% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.